Retraction: Paper “Comparison of Effect of Treatment with Etidronate and Alendronate on Lumbar Bone Mineral Density in Elderly Women with Osteoporosis” by Iwamoto J, et al (Yonsei Med J, (2005) 46, 6, (750-758), 10.3349/ymj.2005.46.6.750);Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis

Yonsei Medical Journal

Volumn 46, Issue 6, 2005, Pages 750-758

  Iwamoto, Jun ^a   Takeda, Tsuyoshi ^a   Sato, Yoshihiro ^b   Uzawa, Mitsuyoshi ^c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mitate Hospital   (Japan)

^c Keiyu Orthopaedic Hospital   (Japan)

Author keywords

Alendronate; Bone mineral density; Etidronate; Osteoporosis; Postmenopausal women

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ETIDRONIC ACID;

ADULT; AGED; AGING; ARTICLE; BACKACHE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUMBAR SPINE; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; SIDE EFFECT; STOMACH PAIN; THIRST; TREATMENT OUTCOME;

EID: 30644462191     PISSN: 05135796     EISSN: 05135796     Source Type: Journal    
DOI: 10.3349/ymj.2019.60.1.117     Document Type: Erratum

References (22)

1. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int 1999;10:183-92.
2. Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, et al. The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Current Therapeutic Research 2002;63:9:606-20.
3. Fujita T, Orimo H, Inoue T, Kaneda K, Sakurai M, Morita R, et al. Double-blind multicenter comparative study with alfacalcidol of etidronate disodium (EHDP) in involutional osteoporosis (in Japanese). Clin Eval 1993;21:261-302.
4. Rogers MJ, Frith JC, Luckman SP, Coxon FR, Benford HL, Monkkonen J, et al. Molecular mechanism of action of bisphosphonate. Bone. 1999;24 (5 Suppi):73S-9S.
5. Cranny A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8.
6. Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med 2000;160:77-85.
7. Orimo H, Sugioka Y, Fukunaga M, Moto Y, Hotokebuchi T, Gorai I, et al. Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 1998;16:139-50.
8. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001; 19:331-7.
9. Lorish CD, Maisiak R. The face scale: a brief, nonverbal method for assessing patient mood. Arthritis Rheum 1986;29:906-9.
10. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
11. Greenspan SL, Parker RA, Ferguson L, Rosen NH, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the longterm response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998;13:1431-8.
12. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000;85:3109-15.
13. Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Mayazaki S, et al. Effects of 1 α-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with osteoporosis. Calcif Tissue Int 1994;54: 370-6.
14. Agarwala S, Sule A, Pai BU, Joshi VR. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford) 2002;41:346-7.
15. Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 1999;18:266-7.
16. Glover D, Lipton A, Keller A, Miller AA, Browing S, Fram RJ, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 1994;74:2949-55.
17. Iwamoto J, Takeda T, Ichimura S. Transient relief of metastatic cancer bone pain by oral administration of etidronate. J Bone Miner Metab 2002;20:228-34.
18. Hortobagyi GN, Terhiault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335:1785-91.
19. Siris E, Chines AA, Altman RD, Brown JP, Johnston CC Jr, Lang R, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 1998;13:1032-8.
20. Nishikaku F, Nakayama T, Nakatsuka M. Analgesic property of bisphosphonate, etidronate in animal models. Jpn Pharmacol Ther 1998;26:457-63 (in Japanese).
21. Tanaka T, Nakayama T, Katsumata T. Etidronate, therapeutic agent for osteoporosis possessing analgesic effect. Bio Clinica 2001;16:57-61 (in Japanese).
22. Pappagallo M, Breuer B, Schneider A, Sperber K. Treatment of chronic mechanical spinal pain with intravenous pamidronate: a review of medical records. J Pain Symptom Manage 2003;26:678-83.